FDA Approves Roche's Gazyva for Primary Membranous Nephropathy

The FDA has approved Roche's Gazyva/Gazyvaro (obinutuzumab) for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. It is the first FDA-approved treatment for the rare autoimmune kidney disease and previously received Breakthrough Therapy Designation.

Approval was based on MAJESTY, a randomized, open-label, multicenter Phase 3 study enrolling 142 adults assigned equally to obinutuzumab or tacrolimus. The trial met its primary endpoint: 36.1% receiving obinutuzumab achieved complete remission of proteinuria at week 104, compared with 5.7% receiving tacrolimus, an adjusted difference of 31.1 percentage points (p<0.001).

Key secondary endpoints also favored obinutuzumab, with complete or partial remission at week 104 occurring in 50% of patients versus 12.9% receiving tacrolimus (p<0.001). Complete remission at week 76 occurred in 36.1% versus 8.6%, respectively (p<0.001).

Roche reported no new safety signals, with findings consistent with the medicine's established safety profile. The results were presented at the European Renal Association Congress in June 2026 and published in the New England Journal of Medicine; data are being submitted to other regulators, including the European Medicines Agency.

Obinutuzumab is a humanized monoclonal antibody targeting CD20 on B cells. Primary membranous nephropathy occurs when the immune system attacks the kidneys' filtering units, allowing protein to leak into urine and potentially causing irreversible kidney damage.

This is the drug's third FDA approval in immune-mediated kidney diseases, following idiopathic nephrotic syndrome and lupus nephritis. The FDA is also reviewing its use in adults with systemic lupus erythematosus, with a decision expected by December 2026.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion